Prism Biolab Co. Ltd. has identified new 7-membered ring-fused compounds acting as Notch signaling inhibitors and reported to be potentially useful for the treatment of neuronal injury and neurodegenerative diseases.
Researchers from Ambrx Inc. and Novocodex Biopharmaceuticals Co. Ltd. presented preclinical data for ARX-305, a next-generation anti-CD70 antibody-drug conjugate (ADC), being developed for the treatment of CD70-expressing cancers.
Grace Science LLC has received FDA clearance of its IND application for GS-100, an AAV9 gene replacement therapy for the treatment of NGLY1 deficiency.
IKZF2 encodes the critical zinc fingers 2 and 3, which are responsible for the DNA binding activity of Helios. Researchers from the University of British Columbia and affiliated organizations have identified new de novo dominant negative variants of the IKZF2 gene.
Abbisko Therapeutics Co. Ltd. has received FDA clearance of its IND application for ABSK-012, a highly selective small-molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4), for advanced solid tumors.
Acetylenic lipids extracted from plants or marine sponges are known to have relevant cytotoxicity against tumoral cells. Previous work has shown that structural modifications to lipidic alkynylcarbinol (LAC) underpin specific changes in its cytotoxic activity.
Kynexis BV has launched with €57 million in series A financing with the aim of using its experience in psychiatry, neurology, and drug discovery and development to advance therapeutics for brain diseases.
RSS
